AAAAAA

   
Results: 1-10 |
Results: 10
Modeling and analysis of a virus that replicates selectively in tumor cells
Authors: Wu, JT Byrne, HM Kirn, DH Wein, LM
Citation: Jt. Wu et al., Modeling and analysis of a virus that replicates selectively in tumor cells, B MATH BIOL, 63(4), 2001, pp. 731-768
A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
Authors: Khuri, FR Nemunaitis, J Ganly, I Arseneau, J Tannock, IF Romel, L Gore, M Ironside, J MacDougall, RH Heise, C Randlev, B Gillenwater, AM Bruso, P Kaye, SB Hong, WK Kirn, DH
Citation: Fr. Khuri et al., A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer, NAT MED, 6(8), 2000, pp. 879-885
Replication-selective microbiological agents: fighting cancer with targeted germ warfare
Authors: Kirn, DH
Citation: Dh. Kirn, Replication-selective microbiological agents: fighting cancer with targeted germ warfare, J CLIN INV, 105(7), 2000, pp. 837-839
Replication-selective adenoviruses as oncolytic agents
Authors: Heise, C Kirn, DH
Citation: C. Heise et Dh. Kirn, Replication-selective adenoviruses as oncolytic agents, J CLIN INV, 105(7), 2000, pp. 847-851
In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy
Authors: Rogulski, KR Freytag, SO Zhang, K Gilbert, JD Paielli, DL Kim, JH Heise, CC Kirn, DH
Citation: Kr. Rogulski et al., In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy, CANCER RES, 60(5), 2000, pp. 1193-1196
Treatment of p53-deficient cancers by adenovirus E1B-region mutants - Frombasic research to the clinic
Authors: Kirn, DH
Citation: Dh. Kirn, Treatment of p53-deficient cancers by adenovirus E1B-region mutants - Frombasic research to the clinic, CANC DRUG, 5, 2000, pp. 537-544
A phase II trial of intratumoral injection with a selectively replicating adenovirus (ONYX-015) in patients with recurrent, refractory squamous cell carcinoma of the head and neck
Authors: Kirn, DH
Citation: Dh. Kirn, A phase II trial of intratumoral injection with a selectively replicating adenovirus (ONYX-015) in patients with recurrent, refractory squamous cell carcinoma of the head and neck, METH MOL M, 35, 2000, pp. 559-574
The discovery and development of selectively replicating adenoviruses as anticancer agents
Authors: Hermiston, T Heise, C Kirn, DH
Citation: T. Hermiston et al., The discovery and development of selectively replicating adenoviruses as anticancer agents, TUMOR TARG, 4(4), 1999, pp. 218-224
Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects
Authors: Heise, CC Williams, A Olesch, J Kirn, DH
Citation: Cc. Heise et al., Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects, CANC GENE T, 6(6), 1999, pp. 499-504
Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy
Authors: Heise, CC Williams, AM Xue, S Propst, M Kirn, DH
Citation: Cc. Heise et al., Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy, CANCER RES, 59(11), 1999, pp. 2623-2628
Risultati: 1-10 |